Insilico Sees Rising Revenue From Deals With AI Firms
THE SO WHAT
AI drug discovery vendors growing revenue via deals with other AI firms suggests a maturing toolchain where model providers, platforms, and domain specialists are vertically interlocking. Pharma operators should map where they sit in this stack now—licensee, co-developer, or data supplier—before terms harden.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechDSC CFO Zou on Strategy, Profitability
DSC edging toward break-even by leaning on data insights and digital infra for used-car dealers shows how thin-margin, fragmented markets are getting rewired by analytics rather than pure volume. If you serve legacy dealer networks, your moat is shifting from inventory access to data-driven pricing and underwriting.
Deep & Emerging TechUS Probes Apex Logistics Over Alleged Nvidia AI Chip Smuggling
Logistics firms now sit directly in the export-control blast radius—alleged AI chip smuggling investigations mean freight partners are effectively part of your compliance perimeter. If your supply chain touches restricted semis, tighten KYC and routing oversight this quarter or expect delays, seizures, and reputational risk.
Deep & Emerging TechUS Says China-Linked Hackers Targeted NASA, Fed and Senate
State-linked actors going after NASA, the Fed, and the Senate is a reminder that advanced compute, models, and critical data are now front-line targets, not back-office IT. Treat your AI infrastructure—weights, training data, orchestration code—with the same threat model you’d apply to core financial or national-security systems.
Deep & Emerging TechAustralia’s Capex Drops as Data Center Spending Hits Air Pocket
A pullback in Australian data center capex suggests the first digestion phase after the initial AI build-out wave—power, permitting, and utilization are starting to constrain pure growth stories. If you’re planning APAC deployments, double-check local capacity timelines instead of assuming infinite rack space at last year’s prices.